Senin, 21 Mei 2012

ABPI And Teenage Cancer Trust CEOs In Keynote Debate At Patient Summit 2012, 29-30 May, London, UK

ABPI And Teenage Cancer Trust CEOs In Keynote Debate At Patient Summit 2012, 29-30 May, London, UK

Main Category: Conferences
Article Date: 21 May 2012 - 9:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions   <!-- rate icon rate article
Patient / Public:not yet rated

Healthcare Prof:not yet rated


Stephen Whitehead, CEO of The Association of the British Pharmaceutical Industry (ABPI) and Simon Davies, CEO of Teenage Cancer Trust will engage in the Keynote Debate at the Patient Summit 2012, it has been announced. With no moderator, the heads will address a variety of topics one-on-one in what has been described as an "armchair debate".

An audience of more than 150 senior industry professionals will be witness to this meeting of minds, marking the beginning of the two day event at the Regents Park Marriott Hotel in London. Up for debate are the increasing costs involved in developing drugs for rarer strains of diseases, the ABPI Code of Conduct and the ever important subject of patient adherence. Stephen Whitehead, Chief Executive of the ABPI, said: "I am really pleased to have been invited by the Patient Summit to speak at the end of May and I look forward to discussing how the pharmaceutical industry, in partnership with others, can help deliver better health care in the UK."

He continued, "The expectations of patients are evolving all the time and in recent years we have seen changes in the way they engage with clinicians, their use of technology and their education. The pharmaceutical industry has been no different and we have seen real transformation in the way companies operate - moving from the old seller/buyer model of the past to working in partnership with the NHS to redesign healthcare pathways. I think now we need to do the same with patient groups and work more closely with them to draw upon their expertise and insight, whilst identifying what people value most about their medicines."

Speaking ahead of the event, Simon Davies, Chief Executive of Teenage Cancer Trust and Chairman of Cancer 52 was positive about the debate and keen to see this as the beginning of a new working partnership. "I very much look forward to sharing a platform with Stephen Whitehead at the Patient Summit. Patient groups have too often been left out of the equation in current health systems and developing productive relationship with the pharmaceutical industry is as important to them as improving relations with the NHS."

He went on to say, "The current economic climate means that we will all have to work hard to ensure that health systems are efficient and effective to deliver what patients need most. That means dialogue, engagement and collaboration, with patients as equal partners in the process. We look forward to a closer working relationship with the pharmaceutical industry to forge new pathways for excellence in healthcare".

On the prospect on a long-term partnership with patient groups, Whitehead was confident. "In the coming months, there are a number of issues which we will be exploring together including pricing medicines under VBP, the development of orphan medicines and the reputational challenges that we both face. I am confident that by working in partnership with patient groups we can deliver significant health benefits to people above and beyond what can be delivered by any party in isolation."

The 2012 Patient Summit is taking place at the Regents Park Marriott Hotel in London, England on 29-30 May. For more information on the event visit: http://www.eyeforpharma.com/patient.

Please use one of the following formats to cite this article in your essay, paper or report:

MLA


APA

Please note: If no author information is provided, the source is cited instead.



Add Your Opinion On This Article

'ABPI And Teenage Cancer Trust CEOs In Keynote Debate At Patient Summit 2012, 29-30 May, London, UK'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



MediLexicon International Ltd Logo

Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.

Everyday Health Network back to top | home | privacy policy

MediLexicon International Ltd Logo MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.

Tidak ada komentar:

Posting Komentar